Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1607495 | 0.95 | KCNH2 (0.31) | KCNH2HRH3 | |
| SCHEMBL4683726 | 0.68 | KCNH2 (0.31) | KCNH2HRH3 | |
| SCHEMBL3683950 | 0.67 | GAA (0.32) | GAASMN1; SMN2KCNH2HRH3 | |
| SCHEMBL467080 | 0.67 | SMN1; SMN2 (0.35) | GAASMN1; SMN2KCNH2HRH3 | |
| SCHEMBL19662088 | 0.66 | KCNH2 (0.50) | GAASMN1; SMN2KCNH2HRH3 | |
| SCHEMBL1607384 | 0.64 | HRH1 (0.35) | GAASMN1; SMN2HSD17B10L3MBTL1 | |
| SCHEMBL533266 | 0.64 | KCNH2 (0.42) | GAASMN1; SMN2HSD17B10L3MBTL1KCNH2 | |
| SCHEMBL12917336 | 0.64 | KDM4E (0.40) | GAASMN1; SMN2HSD17B10L3MBTL1KCNH2 | |
| SCHEMBL2044222 | 0.64 | SMN1; SMN2 (0.43) | GAASMN1; SMN2HSD17B10L3MBTL1 | |
| SCHEMBL28181487 | 0.63 | SMN1; SMN2 (0.42) | GAASMN1; SMN2HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002514157-A | — | — | 2002-05-14 | — | — | JP | claimed |
| US-6346536-B1 | BENZOPYRANOISOQUINOLONE DERIVATIVES; NEURODEGENERATIVE AND BRAIN DISORDERS; REPERFUSION INJURIES; ANTIISCHEMIC AGENTS | GUILFORD PHARMACEUTICALS INC. | 2002-02-12 | — | — | US | claimed |
| EP-0957924-A4 | CERTAIN PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARM INC (US) | 2000-04-12 | — | — | EP | claimed |
| EP-0957924-A1 | CERTAIN PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-24 | — | — | EP | claimed |
| WO-1997048399-A1 | CERTAIN PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
| US-5278162-A | Learning enhancement | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-01-11 | — | — | US | claimed |
| EP-1697345-B1 | MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARM LTD (IE) | 2008-03-12 | — | — | EP | disclosed |
| US-20080039499-A1 | Chemical Compounds | BOWER JUSTIN F | 2008-02-14 | — | — | US | disclosed |
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | ASTRAZENECA AB (SE) | 2007-10-18 | — | — | US | disclosed |
| EP-1761526-A2 | THIAZOLE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2007027454-A1 | HETEROCYCLIC DIHYDROPYRIMIDINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
| EP-1755610-A2 | THIENOPYRIMIDINES AND THIAZOLOPYRIMIDINES FOR USE IN MEDICINE | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| EP-1732931-A1 | METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL | Tibotec Pharmaceuticals Ltd. (IE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005095410-A1 | METHODS FOR THE PREPARATION OF (3R,3aS,6aR) HEXAHYDRO-FURO[2,3-b]FURAN-3-OL | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-10-13 | — | — | WO | disclosed |
| US-20040198799-A1 | Methods of increasing endogenous testosterone levels | LABORATOIRES SERONO SA (CH) | 2004-10-07 | — | — | US | disclosed |
| EP-1355884-A1 | NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002060875-A1 | NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | disclosed |
| US-6346536-B1 | BENZOPYRANOISOQUINOLONE DERIVATIVES; NEURODEGENERATIVE AND BRAIN DISORDERS; REPERFUSION INJURIES; ANTIISCHEMIC AGENTS | GUILFORD PHARMACEUTICALS INC. | 2002-02-12 | — | — | US | disclosed |
| US-6306889-B1 | FUSED HETEROCYCLIC DRUGS FOR CARDIOVASCULAR DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2001-10-23 | — | — | US | disclosed |
| EP-0210545-A2 | Phosphorous containing enzyme inhibitors | MERCK & CO. INC. (US) | 1987-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039499-A1 | Chemical Compounds | CCR1, CCL11, CXCR1 | GAA 4551/4885SMN1; SMN2 4200/4885HSD17B10 2732/4885 |
| US-20040198799-A1 | Methods of increasing endogenous testosterone levels | SHBG, CYP17A1, NR5A1 | GAA 975/4885SMN1; SMN2 2371/4885HSD17B10 74/4885 |
| US-20070244133-A1 | Thienopyrimidines and Thiazolopyrimidines for Use in Medicine | CXCR4, CXCR1, CXCR3 | GAA 4272/4885SMN1; SMN2 4074/4885HSD17B10 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.